Tie-2 Activating Compounds for Ocular Vascular Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular diseases such as diabetic macular edema, age-related macular degeneration, and choroidal neovascularization lack effective methods to stabilize vascular structures and prevent neovascularization, leading to vascular leakage and vision impairment.
Innovation Solution
Development of compounds that activate Tie-2 receptor tyrosine kinase, combined with agents that enhance solubility, to inhibit Human Protein Tyrosine Phosphatase-beta (HPTP-β), thereby stabilizing blood vessels and reducing vascular leakage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for ocular diseases are used, then existing therapeutic options are available, but vascular structures cannot be stabilized and neovascularization cannot be prevented
Solution Approach 1:
The patent uses HPTP-β as an intermediary target to mediate the interaction between Tie-2 receptor activation and vascular stabilization. By inhibiting HPTP-β, the treatment enhances the stabilizing effect of Tie-2 activation on endothelial cells, thereby preventing neovascularization and stabilizing existing vessels. This intermediary mechanism resolves the contradiction by providing a new therapeutic pathway that current treatments lack.
Solution Approach 2:
The patent changes the biochemical parameter of protein phosphorylation status by inhibiting HPTP-β phosphatase activity. This parameter change leads to sustained Tie-2 receptor activation and improved vascular stability. The approach transforms the therapeutic mechanism from direct vascular stabilization to enzyme-mediated phosphorylation control, thereby achieving both reliability and adaptability.
2Reliability
If Tie-2 activating compounds are administered, then vascular stability is improved, but solubility issues limit effective delivery
Solution Approach 1:
The patent employs composite formulation strategies combining Tie-2 activating compounds with solubility-enhancing agents or delivery systems. This composite approach maintains the pharmacological activity of the parent compound while improving its solubility profile for effective ocular delivery. The composite formulation resolves the contradiction between achieving vascular stability and ensuring adequate drug solubility.
3Object-generated harmful factors
If HPTP-β inhibition is achieved, then vascular leakage is reduced, but compound solubility must be enhanced for effective treatment
Solution Approach 1:
The patent introduces solubility-enhancing agents as intermediaries that facilitate the delivery of HPTP-β inhibiting compounds. These intermediaries do not interfere with the primary mechanism of reducing vascular leakage but enable adequate concentrations of the active compound to reach the target site. This resolves the contradiction between achieving therapeutic effect and ensuring sufficient compound solubility.
Data Source
AI summary
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.